COYA

Coya Therapeutics, Inc. (COYA) - Q1 2026 Filing Summary

Business Context and Reporting Period

Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies to enhance Regulatory T cell (Treg) function for neurodegenerative, autoimmune, and metabolic diseases. This Form 10-Q covers the quarterly period ended March 31, 2026. The company is classified as a non-accelerated filer and an emerging growth company. As of May 8, 2026, there were 23,457,183 shares of common stock outstanding.

Key Financial Metrics

Liquidity: The company reported $50.7 million in cash and cash equivalents as of March 31, 2026. Management expects this to fund operations for at least one year beyond the filing date.

Material Changes vs. Prior Period

• Revenue: Collaboration revenue remained relatively flat, decreasing slightly by $6,737 to $251,147. Revenue is derived solely from the DRL Development Agreement related to R&D services.
• Operating Expenses: Total operating expenses decreased by $43,442 to $7.9 million.
  • R&D Expenses: Decreased by $1.1 million to $4.1 million, primarily due to a shift in timing of preclinical activities and a decrease in external costs for preclinical candidates.
  • G&A Expenses: Increased by $1.1 million to $3.8 million. This increase was driven by a $1.0 million non-cash stock-based compensation charge related to the modification of stock options for the former Executive Chairman upon his resignation.
• Capital Raise: In January 2026, the company completed a private placement of 2,522,727 shares at $4.40 per share, generating gross proceeds of approximately $11.1 million. This significantly improved the cash position compared to the prior year.
• Investing Activities: The company utilized $885,000 in cash for the purchase of in-process research and development assets, compared to no investing activity in Q1 2025.

Outlook, Risks, and Unusual Items

• Going Concern: The company has incurred losses since inception and anticipates incurring additional losses until product commercialization. Substantial additional financing will be required. While current cash is expected to fund operations for at least one year, failure to secure future funding could materially adversely affect the company.
• Regulatory Milestone: On May 11, 2026 (subsequent to the period end), the FDA granted Fast Track Designation to COYA 302 for the treatment of Amyotrophic Lateral Sclerosis (ALS).
• Collaboration Agreements:
  • Dr. Reddy's (DRL): The company continues to recognize revenue from R&D services. Deferred revenue related to this agreement was $2.0 million as of March 31, 2026.
  • Methodist License: The company faces a risk of termination if it fails to "Actively Attempt to Develop or Commercialize" within five years of the agreement (deadline approaching October 2025 per risk factors, though the agreement term extends to patent expiration).
• Stock-Based Compensation: A significant portion of the G&A increase was due to a one-time modification of stock options for a departing executive, resulting in $1.0 million of incremental expense.

Investor Verification Checklist

• Verify the timeline for the next anticipated capital raise given the "at least one year" liquidity runway.
• Monitor the progress of the ALSTARS Trial (Phase 2 for COYA 302 in ALS) and the implications of the recent Fast Track Designation.
• Review the specific terms of the Methodist License Agreement regarding the "Active Attempt" clause and potential termination risks.
• Assess the sustainability of R&D expense reductions and whether they impact the timeline for clinical milestones.
• Confirm the status of the $0.3 million milestone payment owed to Dr. Reddy's for the FTD IND approval.